HTI-2's final scope centers TEFCA trust rules rather than its broader proposal
The final rule establishes a federal TEFCA regulatory part while leaving unfinalized proposals withdrawn, a distinction current summaries must preserve.
Editorial figure by Health Interoperability Review. Source context: ASTP/Office of the National Coordinator for Health IT.
Final scope matters more than the proposed-rule headline
The 2024 HTI-2 proposal covered a broad interoperability agenda. The final action is narrower, concentrating on TEFCA governance and related statutory implementation. Content that copies the proposal's full topic list into a current compliance summary can misstate the law.
A standards publication should preserve each provision's lifecycle: proposed, finalized, effective, withdrawn, superseded, or unchanged. That record matters when vendor roadmaps and conference presentations were written before final scope became clear.
TEFCA diligence now includes federal regulatory context
Participation has always involved contractual and technical duties under the Common Agreement, QTF, and operating procedures. HTI-2 adds a regulatory layer aimed at reliable, private, secure, trustworthy, and transparent exchange.
Participants should map obligations across their QHIN agreement, participant terms, internal controls, incident handling, records, and regulatory responsibilities. Product platforms can support evidence and operations, but they do not substitute for governance accountability.
Enterprise buyer test
Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.
A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.
What we will watch next
Health Interoperability Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.